Research progress on dual blockade of TIGIT and PD-1/PD-L1 pathways in tumor im-munotherapy
10.12354/j.issn.1000-8179.2023.20230979
- VernacularTitle:TIGIT和PD-1/PD-L1双重阻断途径在肿瘤免疫治疗中的研究进展
- Author:
Shunna WANG
1
,
2
;
Liulu GAO
;
Xiaofeng ZHENG
;
Guojing XING
;
Lifei WANG
;
Huijuan SHAO
;
Xiaohui YU
;
Jiucong ZHANG
Author Information
1. 甘肃中医药大学第一临床医学院 兰州市 730000
2. 中国人民解放军联勤保障部队第九四〇医院消化内科
- Keywords:
T cell immunoglobulin and immunoreceptor tyrosine-based inhibition motif(ITIM)domain(TIGIT);
programmed death-1 and programmed death-ligand 1(PD-1/PD-L1);
dual blockade;
tumor immunotherapy;
research progress
- From:
Chinese Journal of Clinical Oncology
2023;50(21):1124-1129
- CountryChina
- Language:Chinese
-
Abstract:
Programmed death-1 and programmed death-ligand 1(PD-1/PD-L1)are regulatory immune checkpoint molecules that inhibit T cell activation and,therefore,play an important role in tumor immunotherapy.In recent years,increasing numbers of targeted therapeutic agents have been developed,but single immune checkpoint blockers cannot completely inhibit tumor occurrence,and tumor escape sporadically occurs.Consequently,combination therapy of targeted drugs is considered a useful method to inhibit tumorigenesis and tumor development.T cell immunoglobulin and immunoreceptor tyrosine-based inhibition motif(ITIM)domain(TIGIT)is an inhibitory type 1 poliovirus receptor that has recently been a hotspot of targeted drug therapy research.It has been shown that the combination therapy of TIGIT plus PD-1/PD-L1 can reduce tumor escape and inhibit tumorigenesis more effectively.Therefore,this review summarizes and discusses the progress on the dual blockade of TIGIT and PD-1/PD-L1 pathways in tumor immunotherapy to provide a theoretical basis for tumor im-munotherapy.
